Profluent closed a $106 million Series B to scale its AI‑driven protein design platform into therapeutics, agriculture and biomanufacturing applications, with new investors including Altimeter Capital and Bezos Expeditions. The funding targets expansion of design, discovery pipelines and commercialization efforts. Separately, Eli Lilly formalized TuneLab, opening proprietary AI models to partners under a federated learning framework to accelerate collaborative drug discovery while protecting data privacy. Lilly described the approach as a way to harness collective datasets and speed target identification and in vivo prediction. Combined, these announcements show continued investor appetite for AI‑first platforms and a shift toward partnership models where large pharmas share compute and models to de‑risk early discovery and translate algorithms into clinic‑ready candidates.